Of patients with EGFR-mutated NSCLC, 20–40% experience primary resistance to first or second-generation EGFR-TKIs, which is attributed to genetic alterations (Wang et al., 2016). This evidence concerns the gene EGFR and non-small cell lung carcinoma.